Sanarus Technologies Receives Economic Driver Award At 2015 Beyond The Cloud 3.0 Luncheon

Share Article

BJ Hardman, Chairman and CEO of Sanarus Technologies, honored by Pleasanton Chamber of Commerce

This award illustrates our capacity for innovation and our commitment to providing a better treatment option for women with breast disease.

Sanarus Technologies is pleased to announce that Chairman and CEO BJ Hardman has been named a top executive and recipient of the Economic Driver Award by the Pleasanton Chamber of Commerce. The award was presented Wednesday, November 18th to select business leaders at the 2015 economic driver awards luncheon, Beyond The Cloud 3.0.

In partnership with the City of Pleasanton, the Chamber of Commerce honors chief executives that have made significant contributions to their respective industries and whose companies are drivers of economic growth. Four Pleasanton-based companies were recognized: ZOHO, Title 21 Health Solutions, Fulcrum Bio Energy and Sanarus Technologies.

Approximately 125 people, ranging from local business owners to representatives from the California Assembly and Congress, gathered at the Palm Event Center in the Vineyard for a panel discussion featuring the chief executive honorees. Topics addressed by the panel included market insights, upcoming business trends and economic forecasts for the region and beyond.

Sanarus Technologies is the developer of the Visica 2™ Treatment System, a low-pressure liquid nitrogen cryoablation device currently used for the treatment of both benign and early stage breast tumors.

“This award illustrates our capacity for innovation and our commitment to providing a better treatment option for women with breast disease,” said Hardman. “Pleasanton is a great place to work and live, and we are fortunate to be part of this vibrant business community of economic drivers and trailblazers.”

The patented, FDA-cleared system uses extreme cold (cryo) to destroy tissue (ablation). The Visica 2 Treatment System kills the tumor by freezing it with liquid nitrogen and damaging the adjacent blood supply that fuels tumor growth. Cryoablation offers benefits over surgery in that the procedure is done under local anesthesia, no breast tissue is removed and the shape of the breast is maintained. Leading breast surgeons and interventional radiologists nationwide are using this advanced technology for the treatment of breast tumors as an alternative to surgical lumpectomy.

Hardman founded Sanarus Technologies in 2009 to bring minimally invasive cryoablation-technology products to the breast tumor market. She has broad executive and financial management experience with J&J, Argonaut Group, KPMG Consulting, GE Capital and PointStar Consulting. A frequent industry speaker and author, she received a Master of Science degree in Business Management from the Graduate School of Business at Stanford University, where she was a Sloan Fellow, and holds a Bachelor’s Degree in finance from California State University, San Jose.

About Sanarus Technologies, Inc.
In 2001, the Visica 2 Treatment System was the first system available for cryoablation of fibroadenomas. Since then, our system has been used to successfully treat thousands of patients. The System is FDA-cleared for the ablation of cancerous or malignant tissue and benign tumors. Since 2007, the Visica 2 Treatment System has been used to treat cancer in hundreds of cryoablation-assisted surgeries and dozens of cryoablation-only procedures in clinical trials. At Sanarus, we pride ourselves in developing innovative solutions for the nonsurgical treatment of breast tumors. We are a woman-owned business, headquartered in Pleasanton, CA, and all of our products are manufactured in the USA. Find out more at http://www.sanarus.com

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Karen Hambly
Sanarus Technologies
+1 925-460-6080 Ext: 5713
Email >

Lisa Strickland
@SanarusTech
since: 09/2009
Follow >
Sanarus Technologies
since: 09/2013
Like >
Visit website